Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Sangamo Therapeutics Inc. Stock

Price
Target price
€0.59

€0.59

0.620%
0.0037
0.620%
€8.60
 
07.10.25 / Tradegate WKN: 936386 / Symbol: SGMO / Name: Sangamo Therapeutics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Sangamo Therapeutics Inc. in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Sangamo Therapeutics Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Sangamo Therapeutics

sharewise wants to provide you with the best news and tools for Sangamo Therapeutics, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec

BusinessWire_EN 
0 24.06.25
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.



“This quarter we continued to advance

BusinessWire_EN 
0 13.05.25
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded

BusinessWire_EN 
0 13.05.25
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be

BusinessWire_EN 
0 12.05.25
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close

BusinessWire_EN 
0 06.05.25
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important derisking events in the pathway to a planned BLA submission for isaralgagene civaparvovec, or

BusinessWire_EN 
0 06.05.25
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation

BusinessWire_EN 
0 28.04.25